DBCG phase III randomized trial of hypo- vs standard fractionated RT in 2879 pN+ breast cancer pts

Autor: Offersen, B., Alsner, J., Nielsen, H. M., Bechmann, T., Nielsen, M. H., Mjaaland, I., Kamby, C., Krkove, C., Lorincz, T., Al-Rawi, S., Stoere, E. B., Schreiber, A., Krause, M., Kasti, U., Matthiessen, L. W., Kedzierawski, P., Marinko, T., Luukkaa, M., Skytta, T., Jensen, M., Overgaard, J.

Publikováno v: Offersen, B, Alsner, J, Nielsen, H M, Bechmann, T, Nielsen, M H, Mjaaland, I, Kamby, C, Krkove, C, Lorincz, T, Al-Rawi, S, Stoere, E B, Schreiber, A, Krause, M, Kasti, U, Matthiessen, L W, Kedzierawski, P, Marinko, T, Luukkaa, M, Skytta, T, Jensen, M & Overgaard, J 2022, ' DBCG phase III randomized trial of hypo-vs standard fractionated RT in 2879 pN+ breast cancer pts ', Radiotherapy and Oncology, vol. 170, no. Suppl. 1, OC-0102, pp. S76-S77 . https://doi.org/10.1016/S0167-8140(22)02478-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::746293cf3a2ce30fe8915677af32bc1b
https://vbn.aau.dk/da/publications/fc18c16b-35ac-42c6-93fd-5406b4acfc40